Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now?
Liver transplantation has emerged as a life-saving treatment for several patients with acute liver failure, end stage liver disease and primary hepatic malignancies. However, long term immunosuppressive therapy aiming to reduce the risk of transplant rejection increases the incidence of several complications including malignancies. This is illustrated by the observation of a high ratio between observed and expected cases of lymphoproliferative disorders following liver transplantation. Despite a huge heterogeneity in morphological appearance of these disorders ranging from reactive-like lesions to real lymphomas, they are collectively termed posttransplant lymphoproliferative disorders. In this review we will provide an overview of this rare but challenging disorder as a complication of liver transplantation.
Daan Dierickx, Nina Cardinaels, Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium.
Daan
D
Dierickx
Daan Dierickx, Nina Cardinaels, Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium.
Nina
N
Cardinaels
D020031:Epstein-Barr Virus Infections / Q000276:immunology / Q000821:virology; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D015994:Incidence; D016031:Liver Transplantation / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology / Q000628:therapy / Q000821:virology; D009894:Opportunistic Infections / Q000276:immunology / Q000821:virology; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents
Epstein Barr virus; Liver transplantation; Posttransplant lymphoproliferative disorders